Literature DB >> 25773687

Cardiovascular disease mortality and years of life lost attributable to non-optimal systolic blood pressure and hypertension in northeastern Iran.

Sadaf G Sepanlou1, Roger B Newson2, Hossein Poustchi3, Masoud M Malekzadeh3, Parisa Rezanejad Asl3, Arash Etemadi4, Hooman Khademi5, Farhad Islami6, Akram Pourshams3, Paul D Pharoah7, Christian C Abnet8, Paul Brennan9, Paolo Bofetta10, Sanford M Dawsey8, Farin Kamangar11, Reza Malekzadeh3.   

Abstract

BACKGROUND: High blood pressure is the second most important risk factor of cardiovascular diseases (CVDs) in Iran. It is imperative to estimate the burden of CVDs that can be averted if high blood pressure is controlled at the population level. The aim of the current study was to estimate the avertable CVD mortality in the setting of Golestan Cohort Study (GCS).
METHODS: Over 50,000 participants were recruited and followed for a median of 7 years. The exposures of interest in this study were non-optimal systolic blood pressure (SBP) and hypertension measured at baseline. Deaths by cause have been precisely recorded. The Population Attributable Fraction (PAF) of deaths and Years of Life Lost (YLLs) due to CVDs attributable to exposures of interest were calculated.
RESULTS: Overall, 223 deaths due to ischemic heart disease (IHD), 207 deaths due to cerebrovascular accidents (CVA), and 460 deaths due to all CVDs could be averted if the SBP of all subjects in the study were optimal. Similarly, 5,560 YLLs due to IHD, 4,771 YLLs due to CVA, and 11,135 YLLs due to CVDs could be prevented if SBP were optimal. In all age groups, the avertable deaths and YLLs were higher due to IHD compared with CVA. Deaths and YLLs attributable to non-optimal SBP in women were less than men.
CONCLUSIONS: A very large proportion of CVD deaths can be averted if blood pressure is controlled in Iran. Effective interventions in primary and secondary health care setting are mandatory to be implemented as early as possible.

Entities:  

Mesh:

Year:  2015        PMID: 25773687      PMCID: PMC5784772          DOI: 0151803/AIM.003

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  37 in total

1.  Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.

Authors:  Salim Yusuf; Prem Pais; Alben Sigamani; Denis Xavier; Rizwan Afzal; Peggy Gao; Koon K Teo
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-07-10

2.  The preventive polypill--much promise, insufficient evidence.

Authors:  Fatemeh Malekzadeh; Akram Pourshams; Tom Marshall
Journal:  Arch Iran Med       Date:  2007-07       Impact factor: 1.354

3.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Authors:  S Yusuf; P Pais; R Afzal; D Xavier; K Teo; J Eikelboom; A Sigamani; V Mohan; R Gupta; N Thomas
Journal:  Lancet       Date:  2009-03-30       Impact factor: 79.321

4.  Measuring the burden of disease.

Authors:  R H Morrow; A A Hyder; C J Murray; A D Lopez
Journal:  Lancet       Date:  1998-12-05       Impact factor: 79.321

5.  Cardiovascular risk and all-cause mortality attributable to diabetes: Tehran lipid and glucose study.

Authors:  M Bozorgmanesh; F Hadaegh; F Sheikholeslami; F Azizi
Journal:  J Endocrinol Invest       Date:  2011-05-17       Impact factor: 4.256

Review 6.  A comprehensive review on salt and health and current experience of worldwide salt reduction programmes.

Authors:  F J He; G A MacGregor
Journal:  J Hum Hypertens       Date:  2008-12-25       Impact factor: 3.012

7.  National and subnational mortality effects of metabolic risk factors and smoking in Iran: a comparative risk assessment.

Authors:  Farshad Farzadfar; Goodarz Danaei; Hengameh Namdaritabar; Julie Knoll Rajaratnam; Jacob R Marcus; Ardeshir Khosravi; Siamak Alikhani; Christopher Jl Murray; Majid Ezzati
Journal:  Popul Health Metr       Date:  2011-10-11

8.  Estimating the contribution of selected risk factors in attributable burden to stroke in iran.

Authors:  M Karami; H Soori; A Bahadori Monfared
Journal:  Iran J Public Health       Date:  2012-05-31       Impact factor: 1.429

9.  Comparative quantification of health risks conceptual framework and methodological issues.

Authors:  Christopher JL Murray; Majid Ezzati; Alan D Lopez; Anthony Rodgers; Stephen Vander Hoorn
Journal:  Popul Health Metr       Date:  2003-04-14

10.  Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial.

Authors:  Torben Jørgensen; Rikke Kart Jacobsen; Ulla Toft; Mette Aadahl; Charlotte Glümer; Charlotta Pisinger
Journal:  BMJ       Date:  2014-06-09
View more
  9 in total

1.  Decrescent role of recombinant HSP60 antibody against atherosclerosis in high-cholesterol diet immunized rabbits.

Authors:  Saghar Zonnar; Said Abdul Ghafour Saeedy; Fahimeh Nemati; Mohammad Javad Motamedi; Hamidreza Raeespour; Jafar Amani
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

2.  Twenty-Six-Year Trend of Mortality Rate Due to Ischemic Heart Diseases (IHDs) in Iran: 1990-2015.

Authors:  Shohreh Naderimagham; Kimiya Gohari; Ali Sheidaei; Hamidreza Jamshidi; Alireza Namazi Shabestari; Mitra Modirian; Nazila Rezaei; Farzad Kompani; Bahman Damerchilu; Hamidreza Bahrami-Taghanaki; Bagher Larijani; Farshad Farzadfar
Journal:  Iran J Public Health       Date:  2022-02       Impact factor: 1.479

3.  Deaths from total and premature cardiovascular disease associated with high normal blood pressure and hypertension in rural Chinese men and elderly people.

Authors:  Leilei Liu; Yu Liu; Yongcheng Ren; Yang Zhao; Pei Qin; Dechen Liu; Xu Chen; Cheng Cheng; Feiyan Liu; Chunmei Guo; Qionggui Zhou; Quanman Li; Gang Tian; Minghui Han; Ranran Qie; Xiaoyan Wu; Shengbing Huang; Xinping Luo; Ruirong Cheng; Dongsheng Hu; Jian Wang; Ming Zhang
Journal:  J Hum Hypertens       Date:  2020-07-20       Impact factor: 3.012

4.  Years of Potential Life Lost from Cardiovascular Disease Among Hispanics.

Authors:  Lakshman Manjunath; Jiaqi Hu; Latha Palaniappan; Fatima Rodriguez
Journal:  Ethn Dis       Date:  2019-07-18       Impact factor: 2.006

5.  Associated Factors and Standard Percentiles of Blood Pressure among the Adolescents of Jahrom City of Iran, 2014.

Authors:  Yaser Sarikhani; Seyed Taghi Heydari; Fatemeh Emamghorashi; Fatemeh Jafari; Reza Tabrizi; Saeed Karimpour; Ahmad Kalateh Sadati; Maryam Akbari
Journal:  Int J Pediatr       Date:  2017-01-16

6.  Cardiovascular mortality in a Western Asian country: results from the Iran Cohort Consortium.

Authors:  Noushin Fahimfar; Davood Khalili; Sadaf Ghajarieh Sepanlou; Reza Malekzadeh; Fereidoun Azizi; Mohammad Ali Mansournia; Hamidreza Roohafza; Mohammad Hassan Emamian; Farzad Hadaegh; Hossein Poustchi; Marjan Mansourian; Hassan Hashemi; Maryam Sharafkhah; Akram Pourshams; Farshad Farzadfar; Ewout W Steyerberg; Akbar Fotouhi
Journal:  BMJ Open       Date:  2018-07-05       Impact factor: 2.692

7.  Trends and geographical variation in mortality from coronary disease in Peru.

Authors:  Diego Chambergo-Michilot; Noé Atamari-Anahui; Pedro Segura-Saldaña; Ana Brañez-Condorena; Carlos Alva-Diaz; Daniel Espinoza-Alva
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

8.  Multimorbidity: Epidemiology and Risk Factors in the Golestan Cohort Study, Iran: A Cross-Sectional Analysis.

Authors:  Batoul Ahmadi; Masoomeh Alimohammadian; Mehdi Yaseri; Azam Majidi; Majid Boreiri; Farhad Islami; Hossein Poustchi; Mohammad H Derakhshan; Akabar Feizesani; Akram Pourshams; Christian C Abnet; Paul Brennan; Sanford M Dawsey; Farin Kamangar; Paolo Boffetta; Alireza Sadjadi; Reza Malekzadeh
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 9.  Prevalence of Hypertension in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.

Authors:  Ahmed M Sarki; Chidozie U Nduka; Saverio Stranges; Ngianga-Bakwin Kandala; Olalekan A Uthman
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.